Ipsen gained a little over 2% in Paris, after Barclays this morning confirmed its 'weight in line' recommendation on the stock, and raised its target price from 125 to 135 euros.

In particular, the analyst adjusted his operating expense forecasts for the healthcare group.

It has also revised its sales estimates for Onivyde to reflect the extension of patents until 2033, and updated its first-quarter earnings forecasts.

Lee broker now claims to be 'in line with consensus' and 'above guidance for 2024'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.